Boost to melanoma support in WA
31 January 2020
Melanoma patients and their families across Western Australia will benefit from strengthened and expanded services with the merging of melanomaWA and Melanoma Institute Australia.
One Australian dies from melanoma every five hours and WA is second only to QLD in terms of melanoma incidence across Australia.
Chairman of melanomaWA, Martin Slabbert, said the merger with Melanoma Institute Australia was exciting and would have widespread benefits for the entire West Australian community.
‘The two highly respected organisations will be working together on a regional and national level regarding awareness, education, support, and research,’ Mr Slabbert said.
‘Importantly, the alignment will also provide local, regional, and remote melanoma patients with greater access to medical specialists through Melanoma Institute Australia’s network. This coordinated approach has been well received by patients connected with melanomaWA.’
CEO of Melanoma Institute Australia, Matthew Browne, said the merger would ensure increased resources dedicated to reducing the impact of melanoma on the community in WA.
‘Melanoma Institute Australia is delighted to be merging with melanomaWA,’ Mr Browne said. ‘Melanoma is, unfortunately, Australia’s national cancer and accordingly combining organisations from west coast and the east coast gives us all the best chance of fighting this disease.
‘Joining two strong melanoma organisations immediately brings increased resources and services to melanoma patients as well as a broader coordinated reach in raising awareness about early detection and prevention strategies including sun safety.’
The first fundraising and awareness event of the combined entity will be Melanoma March which will be held in Bunbury on 15th March and at Perth’s Cottesloe Beach on 29th March. Funds raised from the family-friendly Melanoma March events will support melanoma research to pave the way for new and life-saving treatments.
Prof Georgina Long has been appointed President-Elect Society for Melanoma Research (SMR).
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Congratulations are in order for two of our talented researchers.
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.
Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial.
We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.
Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.
We value your privacy and want you to be familiar with how we collect, use and disclose your information.
Melanoma Institute Australia has partnered with IBM Research in Australia to help further advance melanoma identification using cognitive technology.
CEO Carole Renouf chats to senior clinicians and researchers as part of our "4 Questions With..." short video series.
MIA's 'Stop the Spread' campaign has been shortlisted in the 2016 Cannes Lions International Festival of Creativity.